VANTAGENS VS. CUSTOS DOS DIAGNÓSTICOS GENÉTICO-MOLECULARES DA SÍNDROME DE LI-FRAUMENI NO BRASIL:

o que já sabemos?

Authors

  • Marcos André Marques Portella Instituto Mario Penna

DOI:

https://doi.org/10.61229/mpj.v1i2.25

Keywords:

Sistema Único de Saúde, câncer hereditário, síndrome de Li-Fraumeni, rastreio

Abstract

The role of genes is becoming increasingly important in all aspects of medicine, particularly in the field of hereditary cancer screening. In Brazil, there is a higher prevalence of Li-Fraumeni Syndrome (LFS) compared to the world, due to the founding mutation in the TP53 p.R337H gene and despite screening being cost effective, it is not yet incorporated into the Unified Health System (SUS) which is still awaiting the implementation of the law that incorporates screening for BRCA1 and BRCA2 mutations. Brazilian patients with SLF need society's engagement so that they are recognized and benefited from public health policies in the future.    

Downloads

Download data is not yet available.

References

- Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med. 1969 Oct;71(4):747-52. doi: 10.7326/0003-4819-71-4-747. DOI: https://doi.org/10.7326/0003-4819-71-4-747

- Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990 Dec 20-27;348(6303):747-9. doi: 10.1038/348747a0. DOI: https://doi.org/10.1038/348747a0

- Frebourg T, Bajalica Lagercrantz S, Oliveira C, Magenheim R, Evans DG; European Reference Network GENTURIS. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet. 2020 Oct;28(10):1379-1386. doi: 10.1038/s41431-020-0638-4. DOI: https://doi.org/10.1038/s41431-020-0638-4

- McBride KA, Ballinger ML, Killick E, Kirk J, Tattersall MH, Eeles RA, et al. Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol. 2014 May;11(5):260-71. doi: 10.1038/nrclinonc.2014.41. DOI: https://doi.org/10.1038/nrclinonc.2014.41

- Wasserman JD, Novokmet A, Eichler-Jonsson C, Ribeiro RC, Rodriguez-Galindo C, Zambetti GP, Malkin D. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study. J Clin Oncol. 2015 Feb 20;33(6):602-9. doi: 10.1200/JCO.2013.52.6863. DOI: https://doi.org/10.1200/JCO.2013.52.6863

- Matzenbacher Bittar C, de Araújo Rocha YM, Vieira IA, Rosset C, Andreis TF, Sartor ITS, et al. Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil. PLoS One. 2021 Sep 16;16(9):e0251639. doi: 10.1371/journal.pone.0251639. DOI: https://doi.org/10.1371/journal.pone.0251639

- Frankenthal IA, Alves MC, Tak C, Achatz MI. Cancer surveillance for patients with Li-Fraumeni Syndrome in Brazil: A cost-effectiveness analysis. Lancet Reg Health Am. 2022 May 7;12:100265. doi: 10.1016/j.lana.2022.100265. DOI: https://doi.org/10.1016/j.lana.2022.100265

- Pan H, Zhao Z, Deng Y, Zheng Z, Huang Y, Huang S, Chi P. The global, regional, and national early-onset colorectal cancer burden and trends from 1990 to 2019: results from the Global Burden of Disease Study 2019. BMC Public Health. 2022 Oct 12;22(1):1896. doi: 10.1186/s12889-022-14274-7. DOI: https://doi.org/10.1186/s12889-022-14274-7

- Franzoi MA, Rosa DD, Zaffaroni F, Werutsky G, Simon S, Bines J, et al. Advanced Stage at Diagnosis and Worse Clinicopathologic Features in Young Women with Breast Cancer in Brazil: A Subanalysis of the AMAZONA III Study (GBECAM 0115). J Glob Oncol. 2019 Nov;5:1-10. doi: 10.1200/JGO.19.00263. DOI: https://doi.org/10.1200/JGO.19.00263

- Ugai T, Sasamoto N, Lee HY, Ando M, Song M, Tamimi RM, et al. Is early-onset cancer an emerging global epidemic? Current evidence and future implications. Nat Rev Clin Oncol. 2022 Oct;19(10):656-673. doi: 10.1038/s41571-022-00672-8. DOI: https://doi.org/10.1038/s41571-022-00672-8

Downloads

Published

2023-11-30

How to Cite

André Marques Portella, M. (2023). VANTAGENS VS. CUSTOS DOS DIAGNÓSTICOS GENÉTICO-MOLECULARES DA SÍNDROME DE LI-FRAUMENI NO BRASIL: : o que já sabemos?. Mário Penna Journal, 1(2), 68–73. https://doi.org/10.61229/mpj.v1i2.25

Issue

Vol. 1 No. 2 (2023): Mário Penna Journal

Section

Artigos

License

Copyright (c) 2023 Mário Penna Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Autores que publicam nesta revista concordam com os seguintes termos:

  • Declaro que o presente artigo é original, não tendo sido submetido à publicação em qualquer outro periódico nacional ou internacional, quer seja em parte ou em sua totalidade.
  • Declaro, ainda, que uma vez publicado na revista Mário Penna Journal, editada pelo Instituto Mário Penna, o mesmo jamais será submetido por mim ou por qualquer um dos demais co-autores, caso haja, a qualquer outro periódico.
  • Por meio deste instrumento, em meu nome e em nome dos demais co-autores, porventura existentes, cedo os direitos autorais do referido artigo ao Instituto Mário Penna e declaro estar ciente de que a não observância deste compromisso submeterá o infrator a sanções e penas previstas na Lei de Proteção de Direitos Autorias (Nº9609, de 19/02/98).

Ficheiro:Cc-by-nc-sa icon.svg – Wikipédia, a enciclopédia livre

A Revista Mário Penna Journal é licenciada sob uma licença Creative Commons Atribuição-NãoComercial-CompartilhaIgual 4.0 Internacional